Fintel reports that on April 22, 2025, William Blair downgraded their outlook for Medpace Holdings (NasdaqGS:MEDP) from ...

Fintel reports that on April 21, 2025, William Blair initiated coverage of Zillow Group (NasdaqGS:ZG) with a Market Perform ...

William Blair initiated coverage of Xencor (XNCR) with an Outperform rating. The firm believes the biopharmaceutical industry is entering a ...

The broad-based market anxiety increased as the US policy uncertainty rose, says Fidelity. The financial markets were weighed ...

On Monday, William Blair initiated coverage on shares of Xencor, Inc. (NASDAQ: XNCR), currently trading at $9.70, assigning an Outperform rating to the biopharmaceutical company. The stock has ...

Global Payments' agreement to divest its issuer unit is the latest in a series of changes in a complex ownership strategy.

On Monday, William Blair initiated coverage on Context Therapeutics (NASDAQ:CNTX) with an Outperform rating. The firm’s analyst, Matt Phipps, cited the potential of the company’s novel T-cell ...

One wrinkle is the continued weakening of the dollar relative to other major currencies. A dollar that is less valuable would ...

As per the investment manager, the S&P 500 Index delivered a return of −4.3% for Q1 2025, partly because of the performance of growth stocks (−10%). On the other hand, gold (+19%) and commodities ...

In a report released today, Matt Larew from William Blair maintained a Buy rating on 908 Devices (MASS – Research Report). The company’s shares ...

William Blair also issued estimates for Ionis Pharmaceuticals’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($3.84) EPS ...